Table 3.
Other receptors currently studied in clinical trials for the treatment of pancreatic cancer.
| Drug | Target | Combination | Phase | Primary Outcome | Status | ID |
|---|---|---|---|---|---|---|
| CAB-AXL-ADC | AXL | - | I/II | AE, DLT, MTD, ORR | Recruiting | NCT03425279 |
| Relacorilant | Glucocorticoid receptor | Nab-paclitaxel | III | ORR (24 months) | Recruiting | NCT04329949 |
| CX-2029 | CD71 | - | I/II | DLT | Recruiting | NCT03543813 |
| GEN1029 | Death receptor 5 | - | I/II | DLT, AE | Recruiting | NCT03576131 |
| CORT125134 | Glucocorticoid receptor | Nab-paclitaxel | I/II | MTD | Completed | NCT02762981 |
| Ibrutinib | Bruton’s tyrosine kinase | Gemcitabine, Nab-paclitaxel | I/II | DLT, MTD | Not recruiting | NCT02562898 |
| Tisotumab vedotin | Tissue factor | - | II | ORR (1 month) | Recruiting | NCT03485209 |
| Entrectinib | Tropomysin receptor kinase | - | II | ORR (24 months) | Recruiting | NCT02568267 |
AE, adverse events; DLT, dose limiting toxicity; MTD, maximum tolerated dose; ORR, objective response rate.